Andrew Hopkins, Exscientia founder and CEO (Exscientia)

Af­ter years of part­ner­ships, AI biotech Ex­sci­en­tia lands first ma­jor fi­nanc­ing round at $60M

Af­ter years rack­ing up part­ner­ships with biotechs and Big Phar­ma, the AI drug de­vel­op­er Ex­sci­en­tia has land­ed its first large fi­nanc­ing round.

The UK-based com­pa­ny raised $60 mil­lion in a Se­ries C round led by No­vo Hold­ings — more than dou­ble the $26 mil­lion it gar­nered in a Se­ries B 18 months ago. The round will help fur­ther the com­pa­ny’s ex­pan­sion in­to the US and fur­ther what it calls, bor­row­ing a term from the soft­ware world, its “full-stack ca­pa­bil­i­ties,” i.e. its abil­i­ty to de­vel­op drugs from the ear­li­est stage to the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.